VRN07, EGFR exon 20 insertion. Non-Small Cell Lung Cancer
Voronoi’s VRN07 program aims to treat NSCLC by targeting EGFR exon 20 insertion. Voronoi aims to also overcome brain metastasis by developing brain-permeable compound.
Molecular Modeling: a Foundation for Efficient Drug Development
A breakthrough technology that transformed the existing random and intuitive method, by making the targets and candidates for new drugs visually understandable.
VRN02, DYRK1A, Autoimmune diseases
VRN02 program is under development for the treatment of autoimmune diseases, by inhibiting DYRK1A kinase activity. Series of animal experiments have suggested that VRN02 has efficacy for major autoimmune diseases such as rheumatoid arthritis, lupus, psoriasis, inflammatory bowel disease, and atopic dermatitis, and we are expanding into other indications. VRN02 is under development not only as oral pills, but also as topical formulation to apply on skin.
Developing Next-Gen Innovative Drugs
We develop first-in-class and best-in-class global innovative drugs.
Introducing Voronoi Bio
Dr. Son has developed compounds licensed out to global pharmaceuticals, and now introduces Voronoi Bio.
Creating innovation with Harvard
Dr. Bae is in charge of Voronoi’s joint international research, including joint research in Boston with Dr. Nathanael Gray, a professor at Dana-Farber Cancer Institute and Harvard Medical School.
